Request Information
Request Information
Mar 25 2018
TechCrunch
Auris is featured in this TechCrunch article, titled “Monarch is a new platform from surgical robot pioneer Frederic Moll,” for the reveal of its robotic endoscopic technology called the Monarch Platform. With the use of the Monarch Platform’s flexible robotics and controller, a physician can navigate to hard-to-reach places in the periphery of the lung. Auris’s goal is to help clinicians diagnose and treat lung cancer in the early stages, because the prognosis for lung cancer is worse for the patient if it is discovered at an advanced stage.
Dr. Moll, Auris Health CEO, spoke with TechCrunch for the article. He pointed out that traditional manual techniques make it difficult for the physician to get an accurate diagnosis during a bronchoscopy procedure. Manual techniques can also be more traumatic and difficult on the patient. According to Dr. Moll, 40% of the time, there is no diagnosis with manual bronchoscopy techniques. While bronchoscopy is the Auris’s first application for the Monarch Platform, the article also mentions Auris’s plans to apply the platform’s technology to other endoscopy procedures in the future.
Auris raised $500 million in funding through investors like Mithril Capital Management (cofounded by Peter Thiel and Ajay Royan), Lux Capital, Coatue Management and Highland Capital. With funding secured and FDA approval obtained, Auris hopes to bring this technology to hospitals and outpatient centers by the end of the year.
Read More about Auris's Monarch Platform on TechCrunchBronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.